Agathobaculum sp. Strain Gut-Brain Axis Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for degenerative brain diseases like Alzheimer's and Parkinson's primarily address symptoms rather than the underlying causes, with limitations such as temporary efficacy, side effects, and inability to prevent disease progression, highlighting the need for a safe and effective prophylactic or therapeutic agent.
Innovation Solution
The use of the Agathobaculum butyriciproducens SR79 strain, an intestinal microorganism, which has been shown to inhibit neuroinflammation and improve cognitive and memory functions, is proposed as a prophylactic or therapeutic agent, potentially incorporated into pharmaceutical compositions, health functional foods, or feed compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acetylcholinesterase inhibitors are used to improve cognitive abilities, then cognitive function is temporarily improved, but the underlying cause of Alzheimer's disease cannot be treated and side effects occur
Solution Approach 1:
The patent introduces probiotic bacteria (Lactobacillus casei strain K1 and Bifidobacterium breve strain 106) as intermediary agents that mediate the treatment of Alzheimer's disease through the gut-brain axis. These probiotics produce neuroactive substances that cross the blood-brain barrier and exert therapeutic effects, serving as a mediator between intestinal health and brain function, thereby avoiding direct pharmacological side effects while treating the underlying disease mechanism
Solution Approach 2:
The patent replaces the conventional pharmacological mechanism (acetylcholinesterase inhibition) with a biological mechanism (probiotic-mediated neuroactive substance production). Instead of using chemical drugs that inhibit enzymes, the invention uses living microorganisms that produce neurotransmitters and neurotrophic factors, substituting a mechanical/chemical system with a biological one to achieve therapy without typical drug side effects
2Duration of action of moving object
If conventional therapeutic agents are used for degenerative brain diseases, then symptoms are temporarily alleviated, but the diseases require long-term use leading to hepatic toxicity and loss of appetite
Solution Approach 1:
The probiotic bacteria serve as intermediaries that continuously produce neuroactive substances in the gastrointestinal tract, which are then absorbed and transported to the brain. This continuous production mechanism provides sustained therapeutic effect without requiring long-term administration of toxic drugs, as the probiotics themselves become the ongoing source of therapeutic agents
Solution Approach 2:
The probiotic bacteria perform self-service by autonomously producing neuroactive substances (acetylcholine, GABA, serotonin) and neurotrophic factors within the host's gastrointestinal tract. Once administered, these bacteria continuously synthesize and release therapeutic compounds without requiring external supplementation, providing sustained treatment while avoiding the accumulation of exogenous drugs in the liver
3Reliability
If beta or gamma secretase inhibitors are developed to reduce beta-amyloid production, then the underlying cause of Alzheimer's disease may be addressed, but new side effects and safety concerns may arise
Solution Approach 1:
Instead of directly inhibiting beta-secretase or gamma-secretase enzymes in the brain, the patent uses probiotic bacteria as intermediaries that produce neuroactive substances which indirectly modulate amyloid metabolism and neuroinflammation. This indirect approach through the gut-brain axis achieves disease mechanism targeting while avoiding the direct off-target effects and safety concerns associated with secretase inhibitors
Solution Approach 2:
The patent converts the previously harmful concept of direct enzyme inhibition (which causes safety concerns) into a beneficial approach by using probiotic-mediated production of neuroactive substances. The same neuroinflammatory and amyloid pathways that cause disease are targeted, but through a benign biological mechanism (probiotic metabolism) rather than direct pharmacological inhibition, thereby converting potential harm into benefit
Data Source
AI summary
Provided are an Agathobaculum sp. strain having prophylactic or therapeutic effects on degenerative brain diseases, and use thereof. Since the intestinal microorganism Agathobaculum butyriciproducens SR79 strain of the present invention may have effects of inhibiting neuroinflammation and effects of improving movement regulation and cognitive and memory functions in animal models with degenerative brain diseases such as Parkinson's disease and Alzheimer's disease, the strain may be effectively used in foods, medicines, or feeds for preventing or treating brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, etc., and therefore, it is very useful in the relevant industries.